Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S MOTRIN versus TAB PROFEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S MOTRIN versus TAB PROFEN.
CHILDREN'S MOTRIN vs TAB-PROFEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, thereby decreasing pain, fever, and inflammation.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor; reduces prostaglandin synthesis.
200-400 mg orally every 6-8 hours as needed; maximum 1200 mg/day without prescription, extended release forms: 600-800 mg orally twice daily.
400-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day.
None Documented
None Documented
2-4 hours in children; prolonged in neonates and hepatic impairment.
The terminal elimination half-life is 2-4 hours in adults with normal renal function. In elderly patients or those with renal impairment, half-life may be prolonged up to 8-12 hours, requiring dose adjustment.
Renal (90%) as inactive metabolites and conjugates; fecal (<5%).
Renal excretion of unchanged drug accounts for approximately 70-90% of the administered dose, with the remainder eliminated as glucuronide conjugates in urine. Biliary/fecal elimination is minimal (<5%).
Category C
Category C
NSAID
NSAID